These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15320768)

  • 1. Therapeutic potential of hammerhead ribozymes in the treatment of hyper-proliferative diseases.
    Grassi G; Dawson P; Guarnieri G; Kandolf R; Grassi M
    Curr Pharm Biotechnol; 2004 Aug; 5(4):369-86. PubMed ID: 15320768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic hammerhead ribozymes as therapeutic tools to control disease genes.
    Citti L; Rainaldi G
    Curr Gene Ther; 2005 Feb; 5(1):11-24. PubMed ID: 15638708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribozymes in the age of molecular therapeutics.
    Bagheri S; Kashani-Sabet M
    Curr Mol Med; 2004 Aug; 4(5):489-506. PubMed ID: 15267221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribozymes as therapeutic tools for genetic disease.
    Phylactou LA; Kilpatrick MW; Wood MJ
    Hum Mol Genet; 1998; 7(10):1649-53. PubMed ID: 9735387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of preformed hammerhead ribozymes in the gene therapy of cancer (review).
    Sioud M
    Int J Mol Med; 1999 Apr; 3(4):381-4. PubMed ID: 10085409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and validation of therapeutic hammerhead ribozymes for autosomal dominant diseases.
    Fritz JJ; Gorbatyuk M; Lewin AS; Hauswirth WW
    Methods Mol Biol; 2004; 252():221-36. PubMed ID: 15017052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets.
    Yau EH; Butler MC; Sullivan JM
    Exp Eye Res; 2016 Oct; 151():236-55. PubMed ID: 27233447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hammerhead ribozymes as therapeutic agents for bladder cancer.
    Irie A; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S
    Mol Urol; 2000; 4(2):61-6. PubMed ID: 12006244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribozymes: from mechanistic studies to applications in vivo.
    Ohkawa J; Koguma T; Kohda T; Taira K
    J Biochem; 1995 Aug; 118(2):251-8. PubMed ID: 8543555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
    Phylactou LA; Tsipouras P; Kilpatrick MW
    Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA hairpin loops repress protein synthesis more strongly than hammerhead ribozymes.
    Drew HR; Lewy D; Conaty J; Rand KN; Hendry P; Lockett T
    Eur J Biochem; 1999 Nov; 266(1):260-73. PubMed ID: 10542074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HIV-1 gp41 expression with hammerhead ribozymes.
    Fedoruk-Wyszomirska A; Szymański M; Głodowicz P; Gabryelska M; Wyszko E; Estrin WJ; Barciszewski J
    Biochem J; 2015 Oct; 471(1):53-66. PubMed ID: 26209679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribozyme and peptide-nucleic acid-based gene therapy.
    Phylactou LA
    Adv Drug Deliv Rev; 2000 Nov; 44(2-3):97-108. PubMed ID: 11072108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic applications of catalytic antisense RNAs (ribozymes).
    Rossi JJ
    Ciba Found Symp; 1997; 209():195-204; discussion 204-6. PubMed ID: 9383577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA-RNA chimeric hammerhead ribozyme to transforming growth factor-beta(1) mRNA inhibits the exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats.
    Teng J; Fukuda N; Hu WY; Nakayama M; Kishioka H; Kanmatsuse K
    Cardiovasc Res; 2000 Oct; 48(1):138-47. PubMed ID: 11033116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Discovery with Potential to Revitalize Hammerhead Ribozyme Therapeutics for Treatment of Inherited Retinal Degenerations.
    Trujillo AJ; Myers JM; Fayazi ZS; Butler MC; Sullivan JM
    Adv Exp Med Biol; 2019; 1185():119-124. PubMed ID: 31884599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudoknot interaction-mediated activation of type I hammerhead ribozyme: a new class of gene-therapeutic agents.
    Kuriyama M; Kondo Y; Tanaka Y
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(7):466-80. PubMed ID: 24972011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes.
    Fei Q; Zhang H; Fu L; Dai X; Gao B; Ni M; Ge C; Li J; Ding X; Ke Y; Yao X; Zhu J
    Acta Biochim Biophys Sin (Shanghai); 2008 Jun; 40(6):466-77. PubMed ID: 18535745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribozyme- and deoxyribozyme-strategies for medical applications.
    Schubert S; Kurreck J
    Curr Drug Targets; 2004 Nov; 5(8):667-81. PubMed ID: 15578948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.